Strategies for viral inactivation.
The risk of transmission of viruses and other pathogenic organisms by blood can be reduced but not eliminated through donor selection and screening methodologies. The safety of blood derivatives prepared from plasma pools from thousands of donors requires virus inactivation, without which transmission rates approach certainty and with which safety can exceed that of single-donor products. Current inactivation methods have reduced and possibly eliminated the transmission of enveloped viruses, eg, hepatitis B and C viruses and HIV; newer methods, when coupled with existing methods, have the likelihood of providing products whose safety matches that of any pharmaceutical product. Success with the virus inactivation of pooled blood products has fostered research into inactivation methods that are compatible with erythrocyte concentrates and platelet concentrates. The most advanced of these employ light-activatable compounds. If successful, virtually all blood products can be free from transmitting viruses and other pathogenic organisms.
Horowitz
B
B
Melville Biologics, New York, USA.
Ben-Hur
E
E
D000998:Antiviral Agents / Q000494:pharmacology*; D001779:Blood Coagulation Factors / Q000009:adverse effects; D016913:Blood Component Transfusion / Q000009:adverse effects; D001782:Blood Donors; D001798:Blood Proteins / Q000302:isolation & purification; D006801:Humans; D008403:Mass Screening / Q000379:methods; D014777:Virus Diseases / Q000635:transmission*; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents; D001779:Blood Coagulation Factors; D001798:Blood Proteins